Olympus Sets Sights on Growth in Its Refocused Medical BusinessCompany to Focus on Elevating the Standard of Care in Targeted Disease States
December 7, 2021
TOKYO – December 7, 2021 – Olympus Corporation (“Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi), has clarified the direction of its medical business with the aim of achieving further growth and profitability by elevating the standard of care in targeted disease states. The medtech leader’s approach involves greater focus on gastrointestinal, urological, and respiratory care solutions for chronic diseases that will increasingly impact the global population, as well as more focused investment in next-generation technologies that will enhance patient care pathways.
- Plans include sharper focus on gastrointestinal, urological and respiratory care
- Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
- Expanded R&D capabilities, stronger medical and scientific affairs, and other enabling factors will support better execution of Olympus’ medical business
Information posted on this site is current and accurate only at the time of their original publication date, and may now be outdated or inaccurate.